Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.38 |
| ▸ | TDO2 | P48775 | 10/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905676 | 0.84 | IDO1 (0.36) | IDO1TDO2ADORA3ADORA2A | |
| SCHEMBL717876 | 0.82 | IDO1 (0.38) | IDO1TDO2BRD4KMT2A | |
| SCHEMBL720433 | 0.82 | P2RX7 (0.41) | IDO1TDO2ADORA3ADORA2AKMT2A | |
| SCHEMBL717249 | 0.81 | HDAC9 (0.36) | IDO1TDO2KMT2A | |
| SCHEMBL716678 | 0.80 | IDO1 (0.40) | IDO1TDO2ADORA3ADORA2A | |
| SCHEMBL717320 | 0.79 | PDE2A (0.41) | IDO1TDO2KMT2APDE2A | |
| SCHEMBL718429 | 0.78 | PKM (0.41) | IDO1TDO2ADORA3ADORA2AKMT2A | |
| SCHEMBL720503 | 0.78 | IDO1 (0.42) | IDO1TDO2ADORA3KMT2A | |
| SCHEMBL717877 | 0.77 | BCHE (0.42) | ADORA3ADORA2A | |
| SCHEMBL717859 | 0.76 | GCGR (0.39) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | IDO1 2682/4885TDO2 3922/4885BRD4 195/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | IDO1 2682/4885TDO2 3922/4885BRD4 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.